Company Overview and News

0
Red River Resources reveals maiden JORC resource at Liontown East

2018-07-18 proactiveinvestors.com.au
Red River Resources Ltd (ASX:RVR) has revealed its maiden resource of 1.5 million tonnes grading 12.2% zinc equivalent at the Liontown East deposit within the Thalanga Project, Queensland.
RVR

0
Seaco containers efficiently guide miners from pit to port

2018-07-15 australianmining.com.au
The container leasing company has added value to various industries over the past 50 years. Now, it is targeting growth in this regard with mining companies. Australian Mining writes.
RVR

0
Red River awards PYBAR contract extension for West 45 mine

2018-07-13 australianmining.com.au
Red River Resources has awarded PYBAR Mining Services an extension to its contract for the West 45 underground zinc-lead mine.
RVR WSTC

0
Red River Resources extends West 45 mining contract, begins diamond drilling

2018-07-12 proactiveinvestors.com.au
Red River Resources Ltd (ASX:RVR) has awarded PYBAR Mining Services a two year extension to the underground mining contract at West 45 mine within the Thalanga zinc operation in North Queensland.
RVR

0
Red River Resources continues to improve production at Thalanga operation

2018-07-09 proactiveinvestors.com.au
Red River Resources Limited (ASX:RVR) has achieved improved operating performance from its Thalanga Operation in Northern Queensland during the June quarter.
RVR

0
Red River Resources moves forward with Far West development by awarding mining contract

2018-07-06 proactiveinvestors.com.au
Red River Resources Limited (ASX:RVR) has awarded a contract for underground mining at its Far West mine to PYBAR Mining Services.
RVR

0
Red River Resources has fund manager increase stake

2018-07-03 proactiveinvestors.com.au
Red River Resources Ltd (ASX:RVR) has had one of its major shareholders, Tribeca Investment Partners Pty Ltd, increase its stake in the company to 7.27% from 6.26%.
RVR

1
Red River Resources receives vote of confidence from Canaccord Genuity

2018-06-07 proactiveinvestors.com.au
Red River Resources Ltd (ASX:RVR) has hosted broker Canaccord Genuity on-site at its Thalanga Operations in Queensland.
SFRRF SNDFY SFR RVR

1
Red River Resources on track to develop Waterloo deposit with new high-grade drill results

2018-06-06 proactiveinvestors.com.au
Red River Resources Limited (ASX:RVR) is continuing to receive further positive results from drilling at the Waterloo polymetallic massive sulphide deposit, part of its Thalanga Operations in Queensland.
RVR

1
Red River Resources’ blast at Thalanga Far West sets the stage for underground development

2018-05-22 proactiveinvestors.com.au
Red River Resources Limited (ASX:RVR) has successfully completed the main blast at the Far West Box Cut site at its Thalanga Zinc Project in Central Queensland.
RVR

1
Red River awards contract to Pybar

2018-05-20 australianmining.com.au
Red River Resources has launched development of the Far West zinc project, which would be its second underground mine at Thalanga in central Queensland.
RVR

1
Red River Resources begins developing second underground mine at Thalanga Zinc Project

2018-05-17 proactiveinvestors.com.au
Red River Resources Limited (ASX:RVR) has started developing the Far West mine, which will be the second underground mine at the company’s Thalanga Zinc Project in central Queensland.
RVR

1
Red River Resources director buys more shares on market

2018-05-15 proactiveinvestors.com.au
Red River Resources Limited (ASX:RVR) has had 167,830 of its shares purchased on-market by its director Mark Hanlon.
RVR

1
Red River Resources managing director buys shares on market

2018-05-14 proactiveinvestors.com.au
Red River Resources Ltd (ASX:RVR) has received a vote of confidence from its managing director, Mel Palancian, who recently purchased company shares on-market.
RVR

1
Red River Resource managing director buys shares on market

2018-05-13 proactiveinvestors.com.au
Red River Resources Ltd (ASX:RVR) has received a vote of confidence from its managing director, Mel Palancian, who recently purchased company shares on-market.
RVR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:RVR / RED RIVER RESOURCES LIMITED on message board site Silicon Investor.

RVRLF Copper-Gold exploration Reservoir Minerals